Sociedad Americana de Hirudoterapia

Department of Health and Social Affairs — Federated States of Micronesia

FSM DHSA · Micronesia (Federated States) · oceania

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Federated States of Micronesia DHSA — leech-specific authorisation pathway not independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
oceania
Country
Micronesia (Federated States)
Leech status
unregulated
Last ASH review
2026-05-28

Relevant Regulation Codes

  • FSM Pharmaceutical Practice Act and amendments
  • Compact of Free Association arrangements with the United States as applicable
  • Pacific Island Countries (PIC) joint procurement arrangements through the Pacific Pharmaceutical Procurement Service where applicable

Prescriber Requirements

  • FSM DHSA–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

FSM DHSA registration as applicable; English-language labelling (with state-level vernaculars per local convention). Standard cold-chain conditions, with logistical constraints typical of multi-state Micronesian distribution.

Import/Export Rules

FSM DHSA and Quarantine Division clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

FSM's national health insurance scheme coverage depends on inpatient bundling. Compact-of-Free-Association arrangements with the US may apply.

ASH Editorial Notes

Leech-specific authorisation pathway not independently verified by ASH; falls under general medical-device / traditional-medicine framework as appropriate. FSM Compact of Free Association with the United States introduces complex jurisdictional questions for medical-device classification that ASH has not independently mapped.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.